Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
AMBIT BIOSCIENCES CORP (AMBI) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/22/2014 4 Form 4 - Statement of changes in beneficial ownership of securities
12/10/2014 SC 13G/A Senrigan Capital Management Ltd reports a 0% stake in Ambit Biosciences Corp
11/19/2014 SC 13D/A PERSEUS SOROS BIOPHARMACEUTICAL FUND LP reports a 0% stake in Ambit Biosciences Corporation
11/17/2014 8-K Quarterly results
11/13/2014 4 Parkinson David Ross (Director) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Disposed/sold 7,085 options to buy @ $6.66, valued at $47.2k
Disposed/sold 8,000 options to buy @ $6.33, valued at $50.6k
11/12/2014 4 Hasnain Faheem (Director) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Disposed/sold 144,259 options to buy @ $6, valued at $865.6k
Disposed/sold 7,085 options to buy @ $6.66, valued at $47.2k
Disposed/sold 8,000 options to buy @ $6.33, valued at $50.6k
Disposed/sold 20,000 restricted stock units @ $15, valued at $300k
Disposed/sold 775 options to buy @ $600, valued at $465k
Disposed/sold 62 options to buy @ $1680, valued at $104.2k
11/12/2014 4 Hatfield Jeffrey S. (Director) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Disposed/sold 14,000 options to buy @ $6.69, valued at $93.7k
11/12/2014 4 Fuhrman Alan (CFO) has filed a Form 4 on AMBIT BIOSCIENCES CORP
11/12/2014 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
11/12/2014 4 FOLETTA MARK G (Director) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Disposed/sold 14,000 options to buy @ $11.09, valued at $155.3k
Disposed/sold 8,000 options to buy @ $6.33, valued at $50.6k
11/12/2014 4 MARTINO MICHAEL A (CEO) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Disposed/sold 451,899 options to buy @ $6, valued at $2.7M
Disposed/sold 46,083 options to buy @ $11.81, valued at $544.2k
Disposed/sold 91,700 options to buy @ $10.8, valued at $990.4k
Disposed/sold 253,871 restricted stock units @ $15, valued at $3.8M
11/12/2014 4 North Annette (Senior VP and General Counsel) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Disposed/sold 66,000 options to buy @ $11.81, valued at $779.5k
Disposed/sold 40,000 options to buy @ $10.8, valued at $432k
Disposed/sold 63,502 restricted stock units @ $15, valued at $952.5k
11/12/2014 4 Countouriotis Athena (Chief Medical Officer) has filed a Form 4 on AMBIT BIOSCIENCES CORP
10/28/2014 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
10/24/2014 SC 13G Senrigan Capital Management Ltd reports a 5.5% stake in Ambit Biosciences Corp
09/29/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Ambit Biosciences Corporation, Daiichi Sankyo Company, Limited and Charge Acquisition Corp",
"Form of Tender Agreement, by and among Daiichi Sankyo Company, Limited, Charge Acquisition Corp. and the directors and certain stockholders of Ambit Biosciences Corporation",
"Form of Contingent Value Rights Agreement"
09/04/2014 4 ELMS STEVE (Director) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Exercised (in-or-at-the-money) 2,362 shares @ $6.66, valued at $15.7k
Exercised (in-or-at-the-money) 2,362 options to buy @ $6.66, valued at $15.7k
09/04/2014 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amendment to Amended and Restated Bylaws of Ambit Biosciences Corporation"
08/26/2014 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
08/12/2014 10-Q Quarterly Report for the period ended June 30, 2014
08/12/2014 8-K Quarterly results
Docs: "AMBIT BIOSCIENCES ANNOUNCES SECOND QUARTER 2014 OPERATING RESULTS SAN DIEGO — August 12, 2014 — Ambit Biosciences , a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced operating results for the second quarter 2014. The company will host a conference call today to discuss financial results for the quarter and to provide an operational update for the first half of 2014. “We are pleased to have initiated our QUANTUM-R Phase 3 trial, our most notable achievement of the first half,” said Michael Martino, Ambit's President and Chief Executive Officer. “The trial is progressing and sites continue to be activated on plan. This will remain our primary operating focus throughout the year. We..."
08/08/2014 10-K/A Annual Report for the period ended December 31, 2013 [amend]
07/16/2014 4 Hasnain Faheem (Director) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Granted 20,000 restricted stock units @ $0
06/04/2014 4 Hatfield Jeffrey S. (Director) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Granted 14,000 options to buy @ $6.69, valued at $93.7k
06/04/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/19/2014 4 North Annette (Senior VP & General Counsel) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Granted 63,502 restricted stock units @ $0
05/19/2014 4 Countouriotis Athena (Chief Medical Officer) has filed a Form 4 on AMBIT BIOSCIENCES CORP
05/19/2014 4 Fuhrman Alan (CFO) has filed a Form 4 on AMBIT BIOSCIENCES CORP
05/19/2014 4 MARTINO MICHAEL A (President and CEO) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Granted 253,871 restricted stock units @ $0
05/19/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement, under the Company's 2014 Long Term Incentive Program"
05/16/2014 4 Peimer Isai (Director) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Granted 8,000 options to buy @ $6.33, valued at $50.6k
05/16/2014 4 Parkinson David Ross (Director) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Granted 8,000 options to buy @ $6.33, valued at $50.6k
05/16/2014 4 Marchington Allan P (Director) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Granted 8,000 options to buy @ $6.33, valued at $50.6k
05/16/2014 4 FOLETTA MARK G (Director) has filed a Form 4 on AMBIT BIOSCIENCES CORP
Txns: Granted 8,000 options to buy @ $6.33, valued at $50.6k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy